New itch treatment using a combination of neurokinin-1, gastrin releasing peptide, and glutamate receptor antagonists
US-2015320827-A1 · Nov 12, 2015 · US
Compositions and methods for the inhibition of pruritus
US11324725B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11324725-B2 |
| Application number | US-201816761047-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 2, 2018 |
| Priority date | Nov 3, 2017 |
| Publication date | May 10, 2022 |
| Grant date | May 10, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Pharmaceutical compositions comprising a molecular inhibitor of Npr1 are disclosed. Also disclosed are methods of treating, reducing, or preventing acute and/or chronic pruritus in a mammal comprising administering a pharmaceutical composition comprising a molecular inhibitor of Npr1.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier and (b) a molecular inhibitor of Natriuretic polypeptide receptor 1 (“Npr1”), wherein the molecular inhibitor of Npr1 is 1-cyclohexyl-3-(cyclopropylmethyl)-N-((3-methylisoxazol-5-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide. 2. The pharmaceutical composition of claim 1 , wherein the Npr1 is the human isoform of Npr1 (“hNpr1”).
Assignees
Inventors
Classifications
Oxazoles · CPC title
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
Spiro-condensed systems · CPC title
1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title
- A61K31/422Primary
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11324725B2 cover?
- Pharmaceutical compositions comprising a molecular inhibitor of Npr1 are disclosed. Also disclosed are methods of treating, reducing, or preventing acute and/or chronic pruritus in a mammal comprising administering a pharmaceutical composition comprising a molecular inhibitor of Npr1.
- Who is the assignee on this patent?
- Us Health
- What technology area does this patent fall under?
- Primary CPC classification A61K31/422. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).